Bioxyne Limited released its earnings results on Aug 30, 2024. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.

Q: Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,049,228,800 shares outstanding.

Q: What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.

Compare

7 Followers

BXN Stock Chart & Stats

Day’s Range― - ―

52-Week Range<AU$0.01 - AU$0.03

Previous CloseN/A

Volume631.90K

Average Volume (3M)2.12M

Market Cap

AU$63.53M

Enterprise ValueAU$9.57M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-0.34

Next Earnings

Feb 20, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding2,049,228,800

10 Day Avg. Volume2,361,385

30 Day Avg. Volume2,121,502

Standard Deviation0.26

R-Squared0.05

Alpha0.03

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)10.47

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

Bioxyne Limited News

PremiumCompany Announcements

Bioxyne Limited Achieves Record Q2 Results, Plans Expansion into Europe

16d ago

BXN

PremiumCompany Announcements

Bioxyne Limited Reports Record Growth in Q2 FY2025

16d ago

BXN

PremiumCompany Announcements

Bioxyne Limited Upgrades Revenue Forecast Amidst Strong Growth

21d ago

BXN

PremiumCompany Announcements

Bioxyne Limited Expands Manufacturing to Meet Revenue Targets

1M ago

BXN

PremiumCompany Announcements

Bioxyne Limited Director’s Interest Update

2M ago

BXN

PremiumCompany Announcements

Bioxyne Limited Announces Cessation of Securities

2M ago

BXN

PremiumCompany Announcements

Bioxyne Limited Addresses ASX Price Query Compliance

3M ago

BXN

PremiumCompany Announcements

Bioxyne Limited Announces AGM Success with Key Resolutions

3M ago

BXN

See All AU:BXN News

---

Financials

Quarterly

Income Statement >

BXN FAQ

What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was <AU$0.01 and its highest was AU$0.03 in the past 12 months.

What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$63.53M.

When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Feb 20, 2025 which is in 7 days.

How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Aug 30, 2024. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.

Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,049,228,800 shares outstanding.

What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

---

Bioxyne Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-136.57%

Trailing 12-Months

Asset Growth

-62.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioxyne Limited

Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. Some of its products include Progastrim and proTract for Atopic Dermatitis. It operates in two segments: wholesale sales and direct sales. The majority of the revenue is generated from Wholesale sales in the United States and Asia.

---